MD Anderson study finds combination immunotherapy treatment effective before lung cancer surgery

EGFR mutation linked to dramatically increased lung cancer risk

A rare inherited mutation in the Epidermal Growth Factor Receptor gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute.

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Pancreatic tumors can resist immunotherapy by recruiting nearby immune cells to help protect them, according to researchers at The University of Texas at Austin. The findings, published in Nature Communications, also point to a potential new strategy for overcoming resistance and improving cellular therapies.

Ris-Rez reduced risk of death by 54% vs. topotecan in patients with relapsed SCLC, phase III trial in China finds

Hansoh Pharmaceutical Group announced positive overall survival data from ARTEMIS-008, its pivotal phase III trial in China, evaluating the B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) versus topotecan in patients with relapsed small cell lung cancer whose disease progressed following platinum-based first-line therapy.

Rybrevant + chemo delivers longest reported median OS in EGFR exon 20 insertion mutation-positive lung cancer

Patients with with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations treated with intravenous Rybrevant (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy achieved a median OS of nearly three years (34.3 months), compared with 27.9 months for chemotherapy alone, according to the final overall survival analysis of the phase III PAPILLON study.